• Liminatus Pharma will execute a 1-for-50 reverse stock split of its common stock effective at the Aug. 20 close.
• Shares are expected to trade on a split-adjusted basis on Nasdaq under LIMN at the Aug. 21 open.
• Outstanding shares would fall from 67,160,362 to about 1,343,208 on a pro forma July 2 basis.
• Fractional shares will be rounded up to the nearest whole share.
• New post-split CUSIP: 53271X 207.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608181601PRIMZONEFULLFEED9812156) on August 18, 2026, and is solely responsible for the information contained therein.